Abstract
The treatment of metastatic renal-cell carcinoma remains a major challenge. Immunotherapy is a new approach to the treatment of advanced cancer and might offer a window of hope to patients with renal-cell carcinoma. The enthusiasm for this form of cancer therapy is mainly due to the recent advances achieved in immunology and molecular biology. This report reviews our experience with immunotherapy for renal-cell carcinoma. Although it is yet experimental, adoptive immunotherapy and combined cytokine administration appears to be a promising therapeutic modality for a selected group of patients with advanced renal-cell carcinoma.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
